Icatibant Universal Farma

Icatibant, the active ingredient in Icatibant Universal Farma, is a bradykinin B2 receptor antagonist presented as a solution for subcutaneous injection use. It treats acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency.

GNH USA supplies Icatibant Universal Farma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant acts on the bradykinin pathway to relieve swelling in hereditary angioedema.

Hereditary angioedema type I: rapid relief of swelling during acute attacks. Hereditary angioedema type II: rapid relief of swelling during acute attacks. Hereditary angioedema with normal C1‑inhibitor (HAE‑nC1-INH): symptomatic control of acute episodes.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin redness. - Swelling at injection site: transient increase in local tissue volume. - Nausea: occasional upset stomach. - Headache: mild to moderate. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Airway angioedema: swelling that may compromise breathing. - Severe hypotension: marked drop in blood pressure. - Thrombocytopenia: low platelet count. - Stevens‑Johnson syndrome: rare severe skin reaction. - Serum sickness–like reaction: systemic immune response.

Icatibant should be used under medical supervision with attention to patient history and comorbidities. - Pregnancy: consult prescriber; limited safety data available. - Breastfeeding: weigh potential risks and benefits before use. - Renal impairment: monitor renal function; dose adjustment not routinely required. - Concomitant ACE inhibitors: may reduce therapeutic effect; monitor closely. - Known hypersensitivity: avoid in patients with documented allergy to icatibant or its excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with several drug classes; monitoring is advised.

Major Interactions (Avoid): - ACE inhibitors: may diminish icatibant efficacy. - Angiotensin receptor blockers (ARBs): potential reduction in therapeutic effect. - Other bradykinin B2 receptor antagonists: additive antagonism not recommended.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR as icatibant may affect anticoagulation. - NSAIDs: increased risk of local injection‑site reactions. - Diuretics: observe blood pressure for possible fluctuations.